Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M T Petrucci

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Stem Cells (Dayton, Ohio)|August 1, 1995
Is alpha-interferon treatment in multiple myeloma worthwhile?G Avvisati, M T Petrucci
Bailliere'S Clinical Haematology|December 1, 1995
The role of biotherapies (interleukins, interferons and erythropoietin) in multiple myelomaG Avvisati, M T Petrucci, F Mandelli
Recenti Progressi in Medicina|November 10, 2000
[The role of biotherapy in multiple myeloma]M T Petrucci, A Tafuri, F Mandelli
Recenti Progressi in Medicina|October 1, 1990
[Therapy of multiple myeloma and its complications]G Avvisati, A Pulsoni, M T Petrucci, et al.
Leukemia Research Reports|July 4, 2025
Corrigendum to "First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report" [Leukemia Research Reports (2024) Volume 22, 100491]E Amabile, F Fazio, M Martelli, et al.
Leukemia Research Reports|December 17, 2024
First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case reportE Amabile, F Fazio, M Martelli, et al.
Recenti Progressi in Medicina|April 1, 1997
[Therapy of multiple myeloma]G La Verde, A Pulsoni, M T Petrucci, et al.
Journal of Internal Medicine|December 1, 1989
Waldenström's macroglobulinaemia: results of a combined oral treatment in 34 newly diagnosed patientsM T Petrucci, G Avvisati, M Tribalto, et al.
Leukemia & Lymphoma|September 7, 2000
Intravenous melphalan and dexamethasone followed by lymphoblastoid alpha interferon in higher risk multiple myeloma patientsM T Petrucci, G La Verde, M Ribersani, et al.
European Journal of Haematology|March 1, 1989
Intermediate-dose (25 mg/m2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatmentM T Petrucci, G Avvisati, M Tribalto, et al.
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Stem Cells (Dayton, Ohio)|August 1, 1995
Is alpha-interferon treatment in multiple myeloma worthwhile?G Avvisati, M T Petrucci
Bailliere'S Clinical Haematology|December 1, 1995
The role of biotherapies (interleukins, interferons and erythropoietin) in multiple myelomaG Avvisati, M T Petrucci, F Mandelli
Recenti Progressi in Medicina|November 10, 2000
[The role of biotherapy in multiple myeloma]M T Petrucci, A Tafuri, F Mandelli
Recenti Progressi in Medicina|October 1, 1990
[Therapy of multiple myeloma and its complications]G Avvisati, A Pulsoni, M T Petrucci, et al.
Leukemia Research Reports|July 4, 2025
Corrigendum to "First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report" [Leukemia Research Reports (2024) Volume 22, 100491]E Amabile, F Fazio, M Martelli, et al.
Leukemia Research Reports|December 17, 2024
First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case reportE Amabile, F Fazio, M Martelli, et al.
Recenti Progressi in Medicina|April 1, 1997
[Therapy of multiple myeloma]G La Verde, A Pulsoni, M T Petrucci, et al.
Journal of Internal Medicine|December 1, 1989
Waldenström's macroglobulinaemia: results of a combined oral treatment in 34 newly diagnosed patientsM T Petrucci, G Avvisati, M Tribalto, et al.
Leukemia & Lymphoma|September 7, 2000
Intravenous melphalan and dexamethasone followed by lymphoblastoid alpha interferon in higher risk multiple myeloma patientsM T Petrucci, G La Verde, M Ribersani, et al.
European Journal of Haematology|March 1, 1989
Intermediate-dose (25 mg/m2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatmentM T Petrucci, G Avvisati, M Tribalto, et al.
Pageof 6